EGFR, calprotectin and EDN could discriminate between CRC patients and healthy controls (AUCs between 0.737 and 0.803), however, failed to perform reliably in the ‘triage’ setting (Fig. 4). This evidence concerns the gene RNASE2 and colorectal carcinoma.